Advanced Therapy Showcase in Tokyo #2 Live-Streaming Presentation --- Final Timetable

Friday, January 28, 2022 JST

Time (JST)		#	Category	Speaker	Affiliation	Presentation		Country	Time Zone	Local Time		
Start	End					Title	Abstract			Start	End	Date
0800	0805	OR	Opening Remarks	OKANO, Hideyuki, MD, PhD	LINK-J			Japan	JST UTC+9	0800	0805	
0805	0825	S-01	Special Speech	Stephen Majors	The Alliance for Regenerative Medicine (ARM)	State of the Regenerative Medicine Industry in 2022		USA	EST UTC-5	1805	1825	-1
0825	0845	S-02	Special Speech	Owen Smith, MSc CPFA. Partner	4Bio Capital	Advanced Therapies Landscape at the beginning of 2022	What to expect from 2022 after a strong trend in 2021 towards increase investments in the advanced therapies sector? We expect continuous focus on new modalities and increased funds availability for M&A and other financial transactions in that space.	UK	CST UTC-6	1725	1745	-1
0845	0900	C-01	Company Presentation	Christopher Ahuja, MD	Inteligex	Inteligex – Bioengineered Stem Cells to Repair and Regenerate the Injured Spinal Cord	Spinal cord Injury (SCI) is a devastating condition for which there are no effective regenerative treatments. For those who survive the initial injury, a majority are left with significant neurological deficits. In North America, ~20,000 individuals reportedly sustain a new severe traumatic SCI each year, while a 2013 study found ~1,460,000 US residents to be living with paralysis due to SCI and that the annual recurrent cost for Americans approximated ~$40.5 billion USD. Inteligex's goal is to relieve the pain and suffering of patients living with SCI by generating the first effective regenerative treatment using a bioengineered stem cell-based clinical therapy. We have undertaken pre-clinical testing of our bioengineered stem cells and demonstrated superior functional recovery in SCI models. We have also generated numerous, highly-optimized standard operating procedures for generating, culturing, and successfully delivering these clinically-relevant cells. Our research has won numerous international awards and represents the forefront of regenerative therapy for SCI. In the near future, Inteligex will develop a good manufacturing practices compliant cell line, further develop our portfolio of patentable IP, and we anticipate launching a Phase I/IIA clinical trial by the start of 2025. Inteligex is currently in the seed funding round raising 5 million USD.	Canada	EST UTC-5	1845	1900	-1
0900	0915	C-02	Company Presentation	Nina Tandon, PhD, MBA	Epibone, Inc.	Bone and Cartilage Regeneration	EpiBone, Inc. is privately-held regenerative medicine company focused on skeletal reconstruction. Sitting at the intersection of biology and engineering, the company harnesses the power of stem cells to create living solutions that become a seamless part of a patient's own body. EpiBone is currently developing a pipeline of bone, cartilage, and compound (bone and cartilage) products.	USA	EST UTC-5	1900	1915	-1
0915	0930	C-03	Company Presentation	SUGAYA, Kiminobu, PhD	Progenicyte Japan Co., Ltd.	Exosomal delivery of nucleic acid therapeutics to eliminate cancer stem cells and SARS~CoV2	We have developed an exosomal delivery system of DNA-based nucleic acid therapeutics. We apply this technology for therapies of glioblastoma multiforme (GBM), the most aggressive brain tumor, and COVID-19. We successfully eliminated cancer stem cells, which are a cause of the poor prognosis of GBM, by shutting down their drug resistance mechanisms. We recently filed a patent on therapy to destroy SARS-CoV2 viral genome using this technology as well. These therapeutics may not pose any toxicity or unwanted side effect since they target specific genes that do not express in adult humans, and they are effectively delivered by exosomes produced in human mesenchymal stem cells. We plan to market the exosomal DNA delivery system right away and look for partners to develop these therapeutics.	USA	EST UTC-5	1915	1930	-1
0930	0945	C-04	Company Presentation	Colin Lee Novick	DiscGenics, Inc.	DiscGenics Company Overview: a revolutionary approach to a large market in need of innovation	DiscGenics is a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. As the only company in the world to develop an allogeneic cell therapy derived from intervertebral disc cells to treat diseases of the disc, DiscGenics believes it has a unique opportunity to harness the restorative potential of the human body to heal millions of patients suffering from the debilitating effects of back pain. DiscGenics' first product candidate, IDCT, is a homologous, allogeneic, injectable cell therapy that utilizes biomedically engineered progenitor cells derived from intervertebral disc tissue, known as Discogenic Cells, to offer a non-surgical, potentially regenerative solution for the treatment of patients with mild to moderate degenerative disc disease.	USA	JST UTC+9	0930	0945	
0945	0955	–	Break	–	–	–	–	–	–	–	–	–
0955	1010	C-05	Company Presentation	R. Lee Buckler, JD	RepliCel Life Sciences, Inc.	The development and commercialization in Japan of cell-based therapies for regeneration of collagen-depleted tissue	RepliCel Life Sciences is developing and commercializing four products in Japan including two cell-based regenerative therapies focused on regenerating collagen-depleted skin and tendons. RepliCel is also bringing to the Japanese market a unique electronic dermal injection system for the injection of products for which precision and control over dose and delivery are important.	Canada	PST UTC-8	1655	1710	-1
1010	1025	C-06	Company Presentation	Victor Boksha, PhD	NeuroSyntek	NeuroSyntek's "CellOptimiser" and "CellDiagnostic" - high-throughput cell processing platforms for cancer diagnostic and therapy	Cell-based diagnostics and therapies of cancer (including cancer immune-therapies) have to deal with the intrinsic variability of tumor cells. That results in increased costs and reduced reliability of detection – characterization – treatment – monitoring - prognosis pipeline. NeuroSyntekPharma CellOptimiser and CellDiagnostic systems control variability, enhancing efficacy and minimize side effects of cancer treatment. Our high-performance bioprocessing platforms aimed at integration, unification, and cost reduction of the cell processing pipelines from lab to clinics to production. NeuroSyntekPharma CellOptimiser is a scalable, high-throughput parallel cell sorting platform capable of direct processing of blood samples in order of 10 billion cells, using multiple luminescent immunolabeling tags without any restrictions of magnetic beads separation. The CellDiagnostic system is a high-throughput testing-prognostic platform for personal therapies tuning. It combines extracellular sensors with micro-chemically engineered surface properties to study drug-specific responses of cells from patient biopsies.	USA	PST UTC-8	1710	1725	-1
1025	1040	C-07	Company Presentation	Joon Lee, PhD	Cellatoz Therapeutics, Inc.	Corporate Presentation	Cellatoz Therapeutics is a biotech company with differentiated expertise in translational research and process development. Equipped with its proprietary cells and commercialization-ready cGMP grade facility in Korea, Cellatoz specializes in developing advanced innovative cell therapies in regenerative medicine and immuno-oncology fields. The company has four proprietary cells, and two will highlighted: 1) Neuronal Regeneration Promoting Cells (NRPCs), which are Schwann cell-like cells, for the development of treatments for peripheral neuropathies, including Charco-Marie-Tooth disease, 2) Musculo-Skeletal Stem Cells (MSSCs) targeting regeneration of cartilages and treatment of complex fractures.	ROK	KST UTC+9	1025	1040	
1040	1055	C-08	Company Presentation	Nayoung Park	HaplnScience, Inc.	rhHAPLN1, an innovative therapy for tissue restoration as an ECM modulator	HAPLN1 is an endogenous link protein between hyaluronic acid and proteoglycan in ECM found to be often reduced in patients with degenerative tissue diseases. HaplnScience has identified HAPLN1 as a rejuvenation factor in old mouse paired with young mouse in its parabiosis study and is developing rhHAPLN 1 as an anti-aging therapy for various tissue degenerative diseases.	ROK	KST UTC+9	1040	1055	

Time (JST)		#	Category	Speaker	Affiliation	Presentation		Country	Time Zone	Local Time		
Start	End					Title	Abstract			Start	End	Date
1055	1110	C-09	Company Presentation	Sunyoung Kim, D. Phil	Helixmith Co., Ltd.	Novel Concept: Regenerative Medicine for Neuropathy, Neuromuscular, and Neuroischemic Diseases Using a Gene Therapy Approach	Helixmith has developed a novel drug product for neuropathic pain using gene therapy. Engensis® (VM202) is a plasmid DNA product designed to produce two isoforms of HGF in local tissue. Data from Phase 1, Phase 2, and Phase 3 (3-1B) studies for painful diabetic peripheral neuropathy (DPN) indicated that Engensis® may provide a fundamentally new treatment method for patients with neuropathic pain by regenerating damaged nerves and improving microcirculation in affected treatment areas. In addition, Engensus is being tested for ALS (Phase 2 currently enrolling) and CMT (Phase 1 completed). We are looking for potential partners, both strategic and financial.	ROK	KST UTC+9	1055	1110	
1110	1120	–	Break	–	–	–	–	–	–	–	–	–
1120	1135	C-10	Company Presentation	TAKAHASHI, Hideyuki, MSc	PuREC Co., Ltd.	Bone Regeneration with New Cell Therapy “REC”	PuREC is a stem cell company with its proprietary technology to provide the extremely purified stem cell, "REC". Our first therapeutic target is hypophosphatasia, a rare bone formation disease. Many joint diseases, including spinal canal stenosis, are expected to be covered by “REC”. Medical revolution should come with “REC”, as safer and more effective cell therapy treatments!	Japan	JST UTC+9	1120	1135	
1135	1150	C-11	Company Presentation	Stephanie C. Napier	Jiksak Bioengineering, Inc.	Application of iPSC-derived axonal tissue to peripheral nerve repair	Jiksak Bioengineering’s proprietary Nerve Organoid™ tissue consists of an in vivo-like nerve, complete with a long, bundled axon. Using this axon tissue, we have created a peripheral nerve repair product which can act as a scaffold for nerve regrowth. We expect that this technology will be the next-in-class, off-the-shelf nerve repair therapy.	Japan	JST UTC+9	1135	1150	
1150	1205	C-12	Company Presentation	UCHIYAMA, Asako, PhD	Celaid Therapeutics Inc.	Solutions for Hematopoietic Stem Cell Transplantation	Bone marrow (BM) and umbilical cord blood (UCB) transplantation have been the life-saving choice for patients with many life-threatening diseases, such as leukemia, primary immunodeficiency, aplastic anemia etc. However, hematopoietic stem cell (HSC) transplantation has several issues to overcome; donor matching is hard and takes time for BM transplantation while the low CD34+ cell counts in many donated UCB units prevents these units from being used for therapy. Celaid’s platform technology enables HSC to efficiently expand ex vivo regardless of its origin, including cord blood, bone marrow, and peripheral blood. Celaid’s novel growth media is chemically defined, containing no biological materials, such as serum or cytokines, which enables the production of high-quality cell therapy products with low cost. Celaid Therapeutics is developing HSC-based cell therapy products that can be used as an alternative therapy for HSC transplantation by applying Celaid’s platform technology.	Japan	JST UTC+9	1150	1205	
1205	1220	C-13	Company Presentation	YANAGISAWA, Yu, PhD	CellFiber Co., Ltd.	RAMEN Cell Culture	Introducing our cell-encapsulated alginate hollow gel tube for mass culturing and recent progress of process development for manufacturing.	Japan	JST UTC+9	1205	1220	
1220	1300	–	Break	–	–	–	–	–	–	–	–	–
1300	1700	–	The 6th Industry Academic Government Symposium on Regenerative Medicine							–	–	–
1700	1715	C-14	Company Presentation	YAMAUCHI, Rieko	Oncolys BioPharma Inc.	Cancer cure without surgery, for the better quality of life	Oncolys is a pioneer in cancer virotherapy and would like to introduce its Telomelysin / OBP-301, a gene-modified oncolytic adenovirus. We aim for cancer cure without surgery.	Japan	JST UTC+9	1700	1715	
1715	1730	C-15	Company Presentation	OHTA, Keisuke, PhD	Genscript Probio	Help and support for your Cell and Gene Therapy pipelines ~CDMO capabilities of Genscript Probio~	You will find sophisticated and integrated service platforms for Cell and Gene therapy by Genscript Probio.	Japan	JST UTC+9	1715	1730	
1730	1745	C-16	Company Presentation	TANAKA, Jun	Terumo BCT Japan, Inc.	Quantum: Hollow-fiber based automated cell expansion system		Japan	JST UTC+9	1730	1745	
1745	1800	C-17	Company Presentation	Karen Wen, PhD	GenomeFrontier Therapeutics Inc.	Virus-Free Quantum Engine™ for Gene Therapy - Medicine for Next Generation	Introduce our proprietary virus free Quantum Engines including Quantum pBac, a proprietary virus-free piggyBac transposon system, along with Quantum Nufect, a proprietary electroporation kits and iCellar, a CAR-T cell expansion supplement and GOI design, G-Tailor platform and how they work in concert to demostrate in qCART system for a quick and large payload CAR-T production.	Taiwan	CST UTC+8	1645	1700	

Time (JST)		#	Category	Speaker	Affiliation	Presentation		Country	Time Zone	Local Time		
Start	End					Title	Abstract			Start	End	Date
1800	1815	C-18	Company Presentation	Dr Pawan Gupta, MBBS, MD, DNB, PhD	Stempeutics Research	First Allogeneic Mesenchymal Stromal Cells Product Stempeucel ® - approved for marketing in India for Critical Limb Ischemia Management	Critical Limb Ischemia (CLI) due to Buerger's disease (BD) and atherosclerosis Peripheral Artery Disease (PAD) is a major unmet medical need having high incidence of morbidity. We had conducted a phase 2 & phase 4 studies in CLI BD (Registration number in CTRI website: CTRI/2011/11/002107 & CTRI/2018/02/011839) and label extension phase 3 study in CLI PAD (CTRI/2018/06/014436) to assess the efficacy and safety of IM injection of stempeucel® (adult human bone marrow derived, cultured pooled, allogeneic mesenchymal stromal cells) in "no – option" patients of CLI in Rutherford classification - III-5 and Rutherford- III 6 (with gangrene limited to the toes) who are not eligible for revascularization. Stempeucel® is manufactured from BMMSC obtained from healthy volunteers and the product is comprised of pooled allogeneic BMMSCs. Stempeucel® express MSC-associated surface markers, possess potent immunosuppressive activity and secrete various angiogenic factors including VEGF, angiopoietin, IL8 and HGF. Preclinical studies have demonstrated that the pooled product ameliorates limb necrosis, promote blood flow and prevent limb loss in a mouse model of hind limb ischemia. Total of 156 patients of CLI were exposed to stempeucel® in all clinical trials of the two indications. The efficacy in the clinical study was measured by two primary end points - relief of rest pain and healing of ulcer. Initially a dose finding study was done in two doses of - 1 and 2 million/kg in and was compared with standard of care arm. The dose of 2 million / kg was found to be most efficacious. Thereafter, in all the clinical trials the dose of 2 million/kg was used. In the phase 3 and phase 4 clinical trials, both the primary efficacy end points were statistically significant ($p<0.05$). The secondary efficacy end points of increase in Ankle Brachial Pressure Index, in ankle systolic pressure, in total walking distance and quality of life were also statistically significant in phase 3 and phase 4 studies ($p<0.05$). In the phase 2 study, the MRA showed evidence of increase collaterals in the cell arm. Total of 63 adverse events were seen in 38 patients. All AEs were remotely related or unrelated to stempeucel®. The most AEs were – skin ulcer, pyrexia & toe amputation. The patients in the phase 4 study are being followed up for a total duration of 4 years. Hence, IM administration of stempeucel® at a dose of 2 million/kg group has shown clinical benefit and is considered to be effective in treating patients of CLI due to Buerger's disease and atherosclerotic PAD. With this data of safety and efficacy, the CDSCO, India has granted manufacturing and marketing approval for both the indications. Product is being marketed under the brand name "Regenacip" by Cipla – a major Pharma company in India. We are looking for strategic partner to globalize Stempeucel® product for the treatment of Critical Limb Ischemia.	India	IST UTC+5.5	1430	1445	
1815	1830	C-19	Company Presentation	Eric Halioua, Ms, MBA	PDC*Line Pharma	New class of cancer vaccine based on an off-the-shelf Antigen Presenting Cell line	- Presenting our new and scalable therapeutic cancer vaccines based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells - Describing how PDC*line is a much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors Translating the technology for new cancer indications	Belgium	CET UTC+1	1015	1030	
1830	1845	C-20	Company Presentation	Manuel Pires, PhD	Defymed	MailPan®, an immune-protective cell macro-encapsulation device to solve unmet medical needs of chronic diseases	Defymed develops implantable medical devices to improve patient's quality of life. With MailPan®, the aim is to bring cell therapy to a large patient population thanks to an immune-protective device which allows encapsulating different types of secreting cells derived from hESCs, iPSCs, and genetically modified cells. Thanks to two sub-cutaneous ports, it is possible to retrieve the encapsulated cells when necessary and to re-inject a new batch of fresh cells.	France	CET UTC+1	1030	1045	
1845	1855	–	Break	–	–	–	–	–	–	–	–	–
1855	1910	C-21	Company Presentation	Aurelie Grienenberger, PhD	Eligo Biosicience	Eligo Bioscience: improving patients' lives through precision gene editing of the microbiome	Eligo is pioneering gene editing to the microbiome to durably remove bacterial drivers of disease with unprecedented precision. Eligobiotics is a new modality to precisely edit deleterious bacterial genes from disease-driving microbiota. Eligobiotics are delivery vectors derived from bacteriophage that can package a DNA payload, equipped either with a CRISPR nuclease to efficiently remove a deleterious gene by killing the bacteria that carry it, or with a base editor to modify the genetic code of a deleterious gene, for instance to inactivate it, without killing the bacteria expressing it. Eligo is advancing a highly differentiated pipeline of precision gene editing medicines to address unmet medical needs in inflammation, autoimmunity and oncology caused by the expression of specific deleterious bacterial genes from our microbiome.	France	CET UTC+1	1055	1110	
1910	1925	C-22	Company Presentation	Maxime Feyeux, PhD	TreeFrog Therapeutics	iPS-derived cell therapies: scaling-up, maintaining quality, and increasing transplantation efficiency for faster effects with C-Stem	TreeFrog Therapeutics is a French biotech company aiming to provide access to safe and affordable cell therapies for millions of patients. Using proprietary C-Stem technology, TreeFrog Therapeutics announced in April 2021 the production of a single batch of 15 billion hiPSCs in a 10L bioreactor, with an unprecedented expansion factor of 276x per week. Biomimetic C-Stem technology - which overcomes current bottlenecks in cell therapy manufacturing regarding scalability and costs - also introduces : - A new quality quality standard for hiPSC-derived cell products, with preservation of genomic integrity at scale - Ready-to-transplant hiPSC-derived 3D microtissues, for faster time to effect and improved safety. Developing a pipeline of cell therapies with mass-market potential addressing neurodegenerative disorders, cardiac and metabolic diseases, as well as blood and immune disorders, TreeFrog Therapeutics will be opening a technological hub in Kobe in the coming months to drive the adoption of the C-Stem technology in Japan through co-development partnerships.	France	CET UTC+1	1110	1125	
1925	1940	C-23	Company Presentation	Kaare Engkilde, PhD	Amniotics	Amniotics Company presentation	Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) sourced from amniotic fluid. Stem cells based on amniotic fluid, contain a unique richness in high-quality stem cells, yield MSC specific to different tissue or organs, making them optimal for treatments of diseases in these. Amniotics also has an approved GMP facility for production of Advanced Therapy Medicinal Products (ATMPs). Amniotics is looking to establish strategic partnerships with researchers and companies that are interested in developing regenerative medicine targeting diseases with high unmet needs.	Sweden	CET UTC+1	1125	1140	
1940	1955	C-24	Company Presentation	Maria L. Knudsen, PhD	Salipro Biotech AB	Salipro One-Step Reconstitution of GPCRs and Ion Channels for Drug Development	Salipro Biotech's proprietary nano-membrane technology (Salipro®) stabilizes challenging drug targets. With Salipro® it is possible to radically improve workflows to develop therapeutic antibodies as well as small molecules targeting membrane proteins. In addition, Salipro Biotech is pursuing an internal pipeline program with GPCRs and ion channels (e.g. CXCR4, Pannexin1).	Sweden	CET UTC+1	1140	1155	
1955	2010	C-25	Company Presentation	Rhona McIntyre	Touchlight Genetics Ltd.			UK	GMT UTC	1055	1110	